Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis.
Yun-Kyoung SongJaehee LeeJunwoo JoJin Won KwonPublished in: RMD open (2024)
Patients with RA using JAK inhibitors have a significantly lower risk of active tuberculosis than bDMARD users in South Korea; however, patients with RA having LTBI are equally at risk regardless of the treatment received (JAK inhibitor vs bDMARD). Therefore, vigilant tuberculosis monitoring, especially in patients with low adherence to tuberculosis preventive therapy, is essential.
Keyphrases
- rheumatoid arthritis
- mycobacterium tuberculosis
- pulmonary tuberculosis
- hiv aids
- disease activity
- adverse drug
- ankylosing spondylitis
- risk assessment
- interstitial lung disease
- stem cells
- emergency department
- type diabetes
- systemic lupus erythematosus
- rheumatoid arthritis patients
- systemic sclerosis
- metabolic syndrome
- skeletal muscle
- mesenchymal stem cells
- hepatitis c virus
- weight loss
- human immunodeficiency virus
- replacement therapy